Sotrovimab for COVID-19
45th treatment shown to reduce risk in
August 2022, now with p = 0.00048 from 29 studies, recognized in 42 countries.
Efficacy is variant dependent.
No treatment is 100% effective.
Protocols combine treatments.
FDA has revoked sotrovimab's authorization in all regions due to predicted low efficacy with BA.2, and BA.2 exceeding 50% prevalence in all regions.
FDA et al., 5 Apr 2022, preprint, 1 author.